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During 2010, an outbreak of West Nile virus infection 
occurred in Greece. A total of 197 patients with neuroinvasive 
disease were reported, of whom 33 (17%) died. Advanced 
age and a history of heart disease were independently 
associated with death, emphasizing the need for prevention 
of this infection in persons with these risk factors.
A
n outbreak of West Nile virus (WNV) infection 
occurred in Central Macedonia in northern Greece in 
the summer of 2010. The ﬁ  rst cases were diagnosed and 
reported to the Hellenic Centre for Disease Control and 
Prevention (HCDCP) on August 5, 2010 (1). WNV lineage 
2 sequences were later obtained from 3 pools of Culex 
pipiens mosquitoes trapped at 2 sites where cases of West 
Nile neuroinvasive disease (WNND) had occurred (2).
Human cases of WNV disease had not been previously 
reported in Greece. Serosurveys in the early 1960s, 1980s, 
and 2007 identiﬁ   ed WNV antibodies in ≈1% of the 
population, suggesting that WNV, or a related ﬂ  avivirus, was 
circulating in Greece (3–5). In contrast, during 2005–2007, a 
total of 9,590 blood donors were tested by WNV nucleic acid 
ampliﬁ  cation assay and results were negative (6).
The Study
After the outbreak alert was issued in early August 
2010, physicians in Greece were asked to report all cases 
of WNV infection to HCDCP, according to the current 
European Union case deﬁ  nition  (1). Only deaths that 
occurred during hospitalization were attributed to WNV 
infection. Statistical methods are described in the online 
Technical Appendix (www.cdc.gov/EID/content/17/10/11-
0525-Techapp.pdf).
Serum and cerebrospinal ﬂ  uid specimens were tested 
for immunoglobulin (Ig) M and IgG against WNV by 
using an ELISA (WNV IgM capture DxSelect and WNV 
IgG DxSelect; Focus Diagnostics Inc., Cypress, CA, USA). 
Titers >640 were obtained by microneutralization assay 
against WNV in 14/14 patients who were positive for WNV. 
Although tick-borne encephalitis virus (TBEV) and dengue 
virus (DENV) are not prevalent in Greece, specimens 
were also tested for TBEV and DENV by ELISA (TBE/
FSME IgM and TBE/FSME IgG; IBL International Gmbh, 
Hamburg, Germany) and Dengue Virus IgM Capture Dx 
Select and IgG Dx Select (Focus Diagnostics Inc.). All 
specimens were negative for TBEV, and cross-reactivity 
was seen with DENV, mainly for IgM (7).
Overall, 262 patients with WNV infection were 
reported to HCDCP. Of these patients, 197 (75%) had 
neuroinvasive disease (encephalitis, meningitis, or acute 
ﬂ  accid paralysis), and 65 (25%) had WNV fever. This study 
focused on patients with WNND, who were identiﬁ  ed and 
reported more consistently because of disease severity.
Patient disease onset occurred within a 14-week 
interval during July 6–October 5, and the outbreak peaked 
in mid August (Figure 1). Most (94%) patients with WNND 
were reported from the 7 districts of Central Macedonia 
(Figure 2), and the epicenter of the outbreak was in Pella 
and Imathia Districts.
Characteristics of patients with WNND are shown in 
Table 1. Median age of patients with neuroinvasive disease 
was 72 years (range 12–88 years). The attack rate for 
WNND increased signiﬁ  cantly (p = 0.006) with age (Table 
1). The incidence of WNND in older persons (>80 years 
of age) was ≈50× higher than that among the youngest age 
DISPATCHES
1868  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011
Author afﬁ   liations: Hellenic Centre for Disease Control and 
Prevention, Athens, Greece (K. Danis, G. Theocharopoulos, G. 
Dougas, M. Athanasiou, M. Detsis, A. Baka, T. Lytras, K. Mellou, S. 
Bonovas, T. Panagiotopoulos); Aristotle University of Thessaloniki, 
Thessaloniki, Greece (A. Papa); and National School of Public 
Health, Athens (T. Panagiotopoulos)
DOI: http://dx.doi.org/10.3201/eid1710.110525
Figure 1. Reported cases (n = 197) of West Nile neuroinvasive 
disease, by week of symptom onset, Greece, July 6–October 5, 
2010. *Excluding Thessaloniki. West Nile Virus Infection in Greece, 2010
group (<20 years of age). Persons living in rural areas were 
2× as likely to show development of WNND than persons 
living in urban areas (Table 1).
Encephalitis/meningoencephalitis (168 patients, 85%) 
was the most prominent clinical syndrome among patients 
with WNND, followed by meningitis (23, 12%). In addition, 
10 (5%) patients with acute ﬂ  accid paralysis were reported, 6 
(3%) of whom did not have meningitis or encephalitis.
A large proportion (74%) of patients with WNND 
had >1 underlying chronic medical condition; the most 
common were hypertension (39%), heart disease (24%), 
diabetes mellitus (24%), and immunosuppression (10%). 
Patients with WNND were 2× more likely (odds ratio 2.16, 
95% conﬁ  dence interval 1.15–4.04) than patients without 
WNND to have underlying conditions.
Thirty-ﬁ   ve patients died during hospitalization (33 
had WNND), indicating an overall case-fatality rate of 
17% among persons with WNND. Median age of WNND 
patients who died was 78 years (range 49–87 years). The 
case-fatality rate increased substantially (p<0.001) with 
age (Table 2). Median interval from WNV disease onset to 
death was 13 days (range 3–90 days). In 15 (45%) patients 
with WNND who died, the interval between disease onset 
and death exceeded 2 weeks.
WNND patients with >1 underlying disease were 5× 
more likely to have died than patients without underlying 
conditions. Those patients who had heart disease or a 
stroke were ≈2.5× more likely to have died than patients 
without these conditions. However, only older age and 
heart disease were independent predictors of death in the 
ﬁ  nal binomial regression model (Table 2). Supplementary 
results are shown in the online Technical Appendix.
Conclusions
Human cases of WNV infection were detected in 
several European and Mediterranean countries in 2010, 
indicating an increased intensity of viral circulation (8). 
Clinical cases of WNV infection in humans or animals 
had not been previously reported in Greece. The present 
outbreak was the largest in Europe since 1996, when a 
large outbreak was observed in Romania (9). The outbreak 
was located in Central Macedonia, which contains 90% of 
the rice paddies and 70% of the wetland areas in Greece 
and provides a favorable environment for reproduction 
of mosquito vectors (8). The region also hosts one of 
the largest populations of migratory birds in Greece. 
Meteorologic data for the area indicate that 2010 was 
warmer than previous years and unusually wet (8).
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Figure 2. Incidence per 100,000 population of 
197 reported cases of West Nile neuroinvasive 
disease, by township of residence, Greece, 
July–October 2010. Districts with >1 reported 
neuroinvasive cases were divided into townships. 
Dark black lines indicate borders of Central 
Macedonia (north) and Thessalia (south).The overall case-fatality rate among patients with 
WNND (17%) was higher in Greece than that in other 
countries (9–11). The reasons for this ﬁ   nding are not 
clear. Many factors may have played a role in differences 
in the fatality rate. These factors include diagnosis and 
surveillance bias for more severe cases, virus strain, 
host susceptibility, age structure of the population, and 
underlying conditions.
Recent studies on WNV lineage 2 suggested that this 
virus may be underestimated as a cause of neuroinvasive 
disease (2,12). WNV linage 2 isolated from Cx. pipiens 
mosquitoes in the affected areas during this outbreak had 
a nucleotide genetic similarity of 99.6% with the goshawk 
Hungary 2004 strain (12). However, few severe cases of 
WNV infection were reported in Hungary. Experimental 
studies would verify whether the amino acid substitution 
H249P detected in the Greek strain, which is a suspected 
virulence marker in lineage 1 strains, is associated with 
increased virulence (12).
Advanced age and heart disease were found to 
independently predict the risk for WNND-related death. 
The association between age and severe disease has been 
reported (9–11). The contributing factor of age may relate 
to a decrease in the integrity of the blood–brain barrier and 
facilitate access of WNV to the central nervous system (13). 
Heart disease, particularly cardiac arrhythmias, have also 
been recognized as frequent contributors to death caused 
by WNV encephalitis (13–15). Physiologic stress of WNV 
infection may precipitate or exacerbate underlying medical 
conditions resulting in death (14).
These  ﬁ   ndings emphasize the need for primary 
prevention of WNV infection in patients with these 
predisposing conditions and close monitoring for cardiac 
complications in elderly patients hospitalized with WNV 
disease. Vector mosquito control programs, including 
source reduction and larviciding of Culex spp. mosquitoes 
and ongoing public health education and WNV surveillance 
in disease-endemic and newly affected areas, remain the 
cornerstones of WNV disease prevention and control.
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Table 1. Characteristics of 197 patients with West Nile neuroinvasive disease. Greece, July–October 2010* 
Characteristic No. patients  Incidence per 100,000 population  Risk ratio (95% CI) 
Age group, y 
 <20  4 0.18 Reference 
 20–29  3 0.20 1.08  (0.24–4.84) 
 30–39  6 0.34 1.87  (0.53–6.63) 
 40–49  9 0.55 3.03  (0.93–9.82) 
 50–59  18 1.27 6.93  (2.35–20.49) 
 60–69  29 2.44 13.31  (4.68–37.84) 
 70–79  85 8.01 43.74  (16.05–119.2) 
 >80 43 9.63 52.62 (18.89–146.6) 
Sex
 F  88 1.59 Reference 
 M  109 1.97 1.26  (0.95–1.67) 
Place of residence 
 Urban  110 1.38 Reference 
 Rural  87 2.92 2.12  (1.60–2.80) 
Districts in Central Macedonia 
  Chalkidiki  4 3.99 0.76 (0.28– 2.09) 
 Thessaloniki  60 5.27 Reference 
 Pieria  9 7.02 1.33  (0.66–2.69) 
 Serres  21 11.15  2.12  (1.29–3.48) 
 Kilkis  12 13.92  2.64  (1.42–4.91) 
 Imathia  39 27.06  5.14  (3.43–7.69) 
 Pella  41 28.26  5.37  (3.61–7.98) 
 Total  186 15.00  NA
Other districts (region) 
  Etoloakarnania (western Greece)  1 0.46 0.09 (0.01–0.63) 
  Kozani (Western Macedonia)  1 0.65 0.12 (0.02–0.89) 
  Kavala (Eastern Macedonia)  1 0.71 0.14 (0.02–0.98) 
  Larissa (Thessalia)  8 2.80 0.53 (0.25–1.11) 
Total in Greece  197 1.76 NA
*Incidence rates were calculated by using 2008 mid-year population estimates of the Hellenic Statistical Authority as the denominator. CI, confidence  
interval; NA, not applicable. West Nile Virus Infection in Greece, 2010
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Table 2. Predictive factors of death for 197 patients with  West Nile neuroinvasive disease analyzed by univariate and multivariate
analysis, Greece, July–October 2010* 
Characteristic No. deaths, n = 33†  Case-fatality rate, %  Crude risk ratio (95% CI)  Adjusted risk ratio‡ (95% CI) 
Age group, y 
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